

### **16.1.5 Signatures of Principal or Coordinating Investigator(s) and Sponsor’s Responsible Medical Officer, Depending on the Regulatory Authority’s Requirement, and Signature of Responsible Biostatistician**

**STUDY TITLE:** A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older

**STUDY NUMBER:** mRNA-1273-P301

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

**SPONSOR’S SIGNATORY:** Allison August, MD  
VP, Clinical Development, Infectious Diseases  
ModernaTX, Inc.

**See signature and date signed on  
last page of document.**

**SIGNATURE:** \_\_\_\_\_  
Allison August, MD Date

**RESPONSIBLE BIOSTATISTICIAN:** Honghong Zhou, PhD  
Senior Director, Biostatistics  
ModernaTX, Inc.

**See signature and date signed on  
last page of document.**

**SIGNATURE:** \_\_\_\_\_  
Honghong Zhou, PhD Date

**CLIENT:** ModernaTX, Inc.  
200 Technology Square  
Cambridge, MA 02139  
United States

Signature Page for VV-CLIN-002670 v2.0

Approval	Honghong Zhou Clinical 06-Aug-2021 13:20:23 GMT+0000
----------	--

Approval	Allison August Medical 06-Aug-2021 16:52:00 GMT+0000
----------	--

Signature Page for VV-CLIN-002670 v2.0